Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for diabetic macular oedema:
• Ranibizumab for treating diabetic macular oedema (2023) NICE technology appraisal guidance 274
• Aflibercept for treating diabetic macular oedema (2015) NICE technology appraisal guidance 346
• Faricimab for treating diabetic macular oedema (2022) NICE technology appraisal guidance 799
• Brolucizumab for treating diabetic macular oedema (2022) NICE technology appraisal guidance 820
• Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (2024) NICE technology appraisal guidance 953.
This page was last updated: